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Many patients with limited disease small-cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients 
with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of 
this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. 
 
Material and methods 
We analysed patients from a randomized study comparing two 3-week schedules of thoracic radiotherapy 
(TRT) plus standard chemotherapy in LD SCLC. Patients were to receive four courses of cisplatin/etoposide 
and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Responders received 
prophylactic cranial irradiation (PCI). Comorbidity was assessed using the Charlson Comorbidity Index (CCI), 
which rates conditions with increased 1-year mortality. 
 
Results 
157 patients were enrolled between May 2005 and January 2011. Median age was 63 years, 52% were 
men, 16% had performance status 2, and 72% stage III disease. Forty percent had no comorbidity; 34% had 
CCI-score 1; 15% CCI 2; and 11% CCI 3-5. There were no significant differences in completion rates of 
chemotherapy, TRT or PCI across CCI-scores; or any significant differences in the frequency of grade 3-5 
toxicity (p=.49), treatment related deaths (p=.36), response rates (p=.20), progression-free survival (p=.18) or 
overall survival (p=.09) between the CCI-categories. 
 
Conclusion 
Patients with comorbidity completed and tolerated chemo-radiotherapy as well as other patients. There were 
no significant differences in RR, PFS or OS - suggesting that comorbidity alone is not a reason to withhold 












Concurrent chemotherapy and thoracic radiotherapy (TRT) is the recommended treatment for limited disease 
small-cell lung cancer (LD SCLC). Cisplatin plus etoposide is the standard chemotherapy-regimen [1]. 
Several schedules of TRT are being used. Many administer doses of 40-45 Gy, and twice-daily TRT of 45 Gy 
in 30 fractions is one of the recommended schedules [2]. Almost all patients respond to the treatment, and 
the 5-year survival is up to 25%. However, the treatment often causes severe and sometimes fatal toxicity.  
There are concerns about treatment related toxicity, especially from the twice-daily TRT-schedule. 
Some recommend this treatment to “fit” patients – though there is no clear definition of "fit" in this setting [2]. 
A large proportion of patients with LD SCLC suffer from co-existing diseases – mainly due to old age and a 
long history of tobacco smoking [3]. Unfortunately, patients with severe comorbidity are often 
underrepresented in clinical trials, and comorbidity is seldom systematically assessed [4, 5]. Thus, there is a 
need to better understand how these patients should be treated. 
Population-based studies have shown that LD SCLC patients with comorbidity are less likely to 
receive standard chemo-radiotherapy [6-8]. Several studies have demonstrated that comorbidity is an 
independent prognostic factor for survival in cancer. However, the effect on survival in SCLC is unclear as 
some studies have reported negative effects [3, 9-13], while others did not find an influence on survival [7, 
14, 15]. Furthermore, it is not known whether the inferior survival observed in these patients is due to less 
aggressive treatment or whether comorbidity is an independent negative prognostic factor. Few have 
assessed whether patients with comorbidity experience more severe toxicity [16]. 
The aims of this study were to investigate whether LD SCLC patients with co-existing conditions 
completed chemo-radiotherapy to the same extent as those without comorbidity; and whether they 
experienced more severe toxicity or inferior treatment outcomes compared to those without comorbidity. We 
analysed patients enrolled in a randomized clinical trial comparing two schedules of TRT in LD SCLC [17]. 
 
Material and methods 
Approvals 
The study was approved by the Regional Committee for Medical Research Ethics, Central Norway; the 
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From May 2005 until January 2011, 157 patients were enrolled at 18 Norwegian hospitals in a randomized 
phase II trial comparing TRT of 45 Gy in 30 fractions (two fractions per day - BID) with 42 Gy in 15 fractions 
(once daily – OD) in LD SCLC. Eligible patients had SCLC confined to one hemithorax, the mediastinum, 
contralateral hilus and supraclavicular regions; WHO performance status (PS) 0-2; and adequate kidney and 
bone marrow function (leukocytes ≥3.0 x 109/L, platelets ≥100 x 109/L, bilirubin <1.5 x ULN and creatinine 
<125 mol/L). Other active cancers were not allowed. There were no other restrictions with respect to 
comorbidity and no upper age limit. All patients were to receive four courses of cisplatin and etoposide (PE). 
TRT was administered along with the second course of PE. Those with a complete or near complete 
response were offered prophylactic cranial irradiation of 30 Gy in 15 fractions. 
 In the overall study cohort, there were no significant differences between the treatment arms in 
toxicity; treatment related deaths; response rates (OD: 92%, BID: 88%; p=.41), median progression free 
survival (PFS) (OD: 10.2 months, BID: 11.4 months; p=.93), median overall survival (OS) (OD: 18.8 months, 
BID: 25.1 months; p=.61) or 5-year survival (OD: 25%, BID: 23%, p=.80) [17]. Thus, all patients were 
analysed as one cohort in the present study.  
 
Assessments 
Comorbidity was assessed using the Charlson Comorbidity Index (CCI), the most commonly used 
comorbidity index in cancer studies - including many studies of comorbidity in SCLC [6, 10, 11, 13, 14]. The 
CCI was developed in 1987 by identifying conditions with a negative influence on 1-year survival in a cohort 
of 559 hospitalized patients. Conditions are given a value of 1, 2, 3 or 6 representing each conditions relative 
risk of death. These values are summarized to a total score (“CCI-score”) [18]. After training, the first author 
scored comorbidity retrospectively from hospital medical records of the three-month period prior to 
enrolment. 
 Stage of disease was assessed according to TNM v6. Toxicity was assessed according to the 
CTCAE v3.0. Response to treatment was assessed according to RECIST v1.0. 
 
Statistical considerations 
Progression free survival was defined as time from randomization until progression or death, and overall 
survival as time from randomization until death. Survival was estimated using the Kaplan-Meier method and 
compared using the log-rank test. Pearson’s Chi-square and Fisher’s exact tests were used for group 
comparisons. The Cox proportional hazard method was used for multivariate survival analyses, adjusting for 
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study treatment and baseline prognostic factors (age, gender, performance status and stage of disease). 




All 157 patients enrolled in the randomized trial were included in the present study. Baseline characteristics 
are presented in Table 1. The median age was 63 years; 26% were ≥70 years; 52% were men; 84% had PS 
0-1 and 72% stage III disease; and 46% received twice-daily thoracic radiotherapy. Median age was 8-10 
years higher and there were more men among those with the highest CCI. Otherwise, the baseline 
characteristics were balanced between the CCI-categories (Table 1). 
 Median follow-up for progression free survival (PFS) was 59 months (range: 29-97); 34 patients were 
progression-free when the analyses were performed (July 2013). Median follow-up for survival was 90 
months (range: 60-129); 31 patients were alive at the time of the survival analyses (February 2016). 
 
Comorbidity 
Sixty-three patients (40%) had no comorbidity (CCI 0): 54 patients (34%) had CCI 1; 23 (15%) had CCI 2; 13 
(8%) CCI 3; 3 (2%) CCI 4 and 1 (1%) CCI 5. Mean CCI-score was 0.99. Due to the low numbers, patients 
with CCI 3, 4 and 5 were analysed as one category. 
 The most common comorbidities were chronic obstructive pulmonary disease (38%), peptic ulcer 
disease (12%), myocardial infarction (11%), diabetes mellitus (11%), peripheral vascular disease (8%), and 
cerebrovascular disease (8%) (Table 2). 
 Significantly more elderly patients had comorbidity (<70 years: 53%, ≥70 years: 78%, p=.006) and 
they had a significantly higher mean CCI-score (<70 years: 0.78, ≥70 years: 1.59, p<.001). 
 
Study treatment 
There were no significant differences across CCI-scores in the proportion who received four courses of 
cisplatin plus etoposide (p=.09); completed chemotherapy without dose-reductions (p=.07); completed TRT 
as planned (p=.54); or received PCI (p=.30). The overall dose-intensity of the chemotherapy was 92%, and 
there were no significant differences across CCI-scores (p=.25). Patients with CCI 3-5 received significantly 
less second-line chemotherapy (p=.010) (Table 3). 
 
 




Grade 3-5 toxicity occurred in 141 patients (92%) in the overall population, 136 patients (89%) experienced 
grade 3-5 haematological and 106 patients (69%) grade 3-5 non-haematological toxicity. The most common 
non-haematological toxicities were neutropenic infections (41%), radiation esophagitis (32%) and infections 
without neutropenia (10%). Radiation pneumonitis was observed in eight patients (5%). Grade 5 toxicity was 
only observed from radiation pneumonitis (n=4, 3%) (Table 4). 
 There were no statistically significant differences in the frequency of any grade 3-5 toxicity (p=.49), 
grade 3-5 haematological toxicity (p=.23), or grade 3-5 non-haematological toxicity (p=.98) across CCI-
scores. CCI-scores were not significantly associated with neutropenic infections (p=.86), radiation 
esophagitis (p=.36) or radiation pneumonitis (p=.76) (Table 4). 
 There were seven treatment related deaths (Table 4): Radiation pneumonitis (n=4), coronary 
disease (n=1), haemoptysis (n=1) and respiratory failure (n=1). There were no significant associations with 
CCI-scores: One patient had CCI 0; four patients had CCI I; one patient CCI 2; and one patient CCI 3 
(p=.36). 
 
Response rates and progression free survival (PFS) 
Overall, 90% of patients had an objective response at CT evaluation within three weeks after completing 
study treatment (Table 5). There were no significant differences in response rates across CCI-scores (CCI 0: 
95%, CCI 1: 87%, CCI 2: 87%, CCI 3-5: 82%; p=.20). 
Median progression-free survival for the whole population was 10.6 months, the 1-year PFS was 
47%. There was no significant difference in median PFS between CCI categories (p=.18), but patients with 
CCI 1 (31%) had a lower 1-year PFS than other patients (52%-65%) (p=.032) (Figure 1). 
 
Survival 
Median overall survival was 22.7 months, 2-year survival was 47% and the 5-year survival was 24% in the 
whole cohort (Figure 1). Patients with CCI 1 had the lowest 2-year survival (CCI 0: 56%, CCI 1: 37%, CCI 2: 
48%, CCI 3-5: 47%; p=.26), 5-year survival (CCI 0: 27%, CCI 1: 19%, CCI 2: 26%, CCI 3-5: 29%; p=.67) and 
median overall survival (CCI 0: 30.6 months, CCI 1: 15.1 months, CCI 2: 23.0 months and CCI 3-5: 23.0 
months; p=.09); but the difference was not statistically significant (Figure 1). 
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 Neither CCI-score (p=.23), nor any of the baseline characteristics were independent prognostic 
factors in multivariate analyses: Age (p=.27), gender (p=.82), TRT-schedule (p=.45), disease stage (p=.10) 
and performance status (p=.52) (Table 6). 
 
Discussion 
In our cohort of patients with LD SCLC receiving concurrent chemo- and radiotherapy, we found that the 
majority (60%) had co-existing diseases associated with increased 1-year mortality according to the 
Charlson Comorbidity Index. Patients aged 70 years or older had more comorbidity than younger patients. 
There were no differences in completion of study treatment, and there were no significant differences in the 
frequency of severe toxicity, response rates, progression free survival or survival across CCI-categories.  
Interestingly, we did not find any differences in completion of study treatment between those with 
comorbidity and other patients. In population-based studies, patients with comorbidity received less 
treatment, but it is not clear whether this was due to more toxicity or concerns about toxicity [11, 16]. In 
contrast to our study, comorbidity was associated with more toxicity in one population-based study of 368 LD 
SCLC patients ≥75 years [16]. Otherwise, there is little evidence for withholding standard therapy from these 
patients due to concerns about tolerability. 
There were numerical differences in median PFS and overall survival, mainly because the values for 
patients with CCI 1 were lower than for the other patients. Thus, we did not find a uniform trend towards 
decreasing PFS or survival time with increasing CCI-scores, and all CCI-categories had longer median 
overall survival than in studies of extensive disease SCLC [1, 19]. The lack of prognostic impact of 
comorbidity has also been observed in several other studies of SCLC [7, 14, 15, 20]. However, the literature 
is not consistent since others have demonstrated an inferior survival among patients with comorbidity [3, 9-
13]. The studies are, however, not necessarily comparable. Three of the studies reporting that comorbidity 
was a negative prognostic factor, were population-based studies, and not studies of patients receiving 
specific therapy [3, 11, 12]. There were variations in age distribution, extent of disease and treatment 
administered, and data on important prognostic factors such as performance status were not available in all 
studies [12]. Furthermore, comorbidity was assessed using different methods. The choice of index might 
influence the results - as illustrated by two studies who demonstrated different prognostic impact of 
comorbidity when several methods for comorbidity-assessment were compared [10, 13]. No standard 
method for measuring comorbidity in cancer studies has been established, but CCI is the most widely used 
[21].  
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A possible explanation for the lack of influence on prognosis from comorbidity might be that the 
impact on survival of the conditions listed in the CCI has changed over time. The CCI was developed in 
1987, and improved classification and treatment may have changed the prognosis of conditions specified in 
the index. Furthermore, the CCI does not take into account the severity of all conditions (e.g. COPD and 
ischemic heart disease).  Another possible explanation is the relatively short median survival time in the 
overall study population. Read et al. found that the influence of comorbidity on prognosis in cancer patients 
depends on the overall survival time and that it is less important in cancers with a short expected survival 
time such as lung cancer [22].  
A potential limitation of our study is the retrospective assessment of comorbidity, and that most of the 
comorbidity assessment was done by one author - although CCI is know to have a high inter-rater-reliability 
[23]. All co-existing conditions may not be accurately described or mentioned at all in the medical records. 
However, in a previous study, by carefully checking the medical records and lists of medication, trained 
oncologists registered more comorbidity from hospital medical records than what attending physicians 
recorded at inclusion in a study of advanced non-small-cell lung cancer [24]. 
The most important limitation to this study is the sample size. Due to the low numbers, patients with 
CCI-scores 3-5 were analysed as one category, but the results did not change when these CCI-categories 
were analysed separately (data not shown). Strengths of the study include a higher proportion of PS 2 
patients than in other studies of LD SCLC [4, 5], and all patients received standard, concurrent chemo-
radiotherapy. 
There were few restrictions with respect to comorbidity in the eligibility criteria, but it is still possible 
that some patients have been considered ineligible for the study due to co-existing conditions. This is not 
possible to assess accurately since we did not collect data on patients with LD SCLC who were not enrolled 
in the main trial, and the Norwegian Cancer Registry does not contain detailed information about disease 
stage or comorbidity. The prevalence of comorbidity (60%) in our cohort was similar to former, population-
based studies of all stages SCLC (range: 56%-67%) [3, 7, 11]. The proportion of patients with CCI ≥2 in our 
cohort (26%) was higher than in a study of 174 patients with LD SCLC (12%) [6], but only three percent of 
our patients had a CCI ≥4. In a population-based study 23% of patients (n=7845), and 18% of those 
receiving chemotherapy (n=4820), had a CCI ≥4 [11]. However, patients with extensive disease SCLC were 
included in that study and 8% had PS 3-4. In the only other study of LD SCLC patients receiving concurrent 
chemo- and radiotherapy (n=73), 15% of patients had a CCI of 5-8 [13]. The studies are not necessarily 
comparable since the methods for assessing comorbidity varied. In studies using CCI, different cutoff-values 
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and categorizations of CCI-scores have been applied, and there is no established definition of “severe” 
comorbidity with respect to CCI-scores in cancer studies. Furthermore, there is limited information about 
what treatment patients received in these studies, and only one, small study (n=73) reported frequency and 
severity of comorbidity in LD SCLC patients receiving concurrent chemo- and radiotherapy.[13] 
There have been concerns about toxicity from concurrent chemo- and radiotherapy, especially from 
the twice-daily schedule of thoracic radiotherapy. The European Society of Medical Oncology recommends 
that patients in a good performance status are treated with concurrent chemo-radiotherapy. Thus, we did not 
include PS 3-4 patients. Furthermore, ESMO recommends that twice-daily TRT is offered fit patients, 
although "fit" has not been defined in this setting [2]. It has been reported that physicians offer alternative 
treatment schedules to patients with severe comorbidity [6-8]. Our study suggests that patients with 
performance status 0-2 and organ function adequate for standard chemotherapy tolerate standard 
concurrent chemo- and radiotherapy even if they suffer from co-existing diseases. Interestingly, the 
proportion of long-time survivors in our study was similar for all CCI-categories. However, only limited 
evidence can be obtained from a small study assessing comorbidity retrospectively, and our results are not 
necessarily generalizable to all patients with LD SCLC due to the possible exclusion of patients with 
comorbidity despite wide eligibility criteria. Systematic, prospective assessment of comorbidity should be 
conducted prospectively in future trials before treatment strategies can be outlined for patients with 
comorbidity. Building on the experience from this randomized trial, we are currently running a Nordic 
randomized trial comparing twice-daily TRT of 45 Gy/30 fractions and 60 Gy/40 fractions. In this trial, a 
prospective, comprehensive geriatric assessment is performed on all patients including measuring 
comorbidity on the CCI; patient reported frailty (G8); nutritional status (PG SGA); timed-up-and-go and 5 
meter walk test; patient reported health-related quality of life (EORTC QLQ C30); and assessment of lean 
body muscle mass (protocol available on nlcg.no/node/113). A comprehensive Geriatric Assessment 
appears to provide more prognostic and predictive information than comorbidity assessment alone [20, 25]. 
 
Conclusion 
Patients with comorbidity completed and tolerated concurrent chemo- and radiotherapy for limited-disease 
small-cell lung cancer as well as other patients. There were no significant differences in response rates, 
progression free survival or overall survival - suggesting that comorbidity alone is not a reason to withhold 
standard, concurrent chemo- and radiotherapy in LD SCLC. 
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Figure 1 Progression free survival and overall survival according to CCI-scores
p =.18 (log-rank) p =.09 (log-rank)
Median (95% CI)  PFS 1-year (95% CI) PFS
Overall 10.6 (8.1–13.0)months 47 (39–55) %
CCI 0 13.3 (10.3–16.2)months 54 (41–67) %
CCI 1 8.2 (6.9–9.5) months 31 (20–46) %
CCI 2 12.2 (4.5–19.9)months 52 (31–73) %
CCI 3-5 12.8 (11.0–14.7)months 65 (38–86) %
Median (95% CI) OS 2-year (95% CI) OS 5-year (95% CI) OS
Overall 22.7 (19.1–26.3) months 47 (39–55) % 24 (18–32) %
CCI 0 30.6 (20.5–40.6) months 56 (42–68) % 27 (17–40) %
CCI 1 15.1 (9.2–21.0) months 37 (24–51) % 19 (9–31) %
CCI 2 23.0 (2.0–44.1) months 48 (27–69) % 26 (10–48) %
CCI 3-5 23.0 (12.5–33.4)months 47 (23–72) % 29 (10–56) %
Overall (n=157) CCI 0 (n=63) CCI 1 (n=54) CCI 2 (n=23) CCI 3-5 (n=17)
n % n % n % n % n %
Age Median (range) 63 (40-85) 62 (40-79) 64 (41-79) 64 (51-85) 72 (56-79)
<70 116 74% 54 86% 39 72% 17 74% 6 35%
≥70 41 26% 9 14% 15 28% 6 26% 11 65%
Gender Women 76 48% 34 54% 28 52% 9 39% 5 29%
Men 81 52% 29 46% 26 48% 14 61% 12 71%
Performance status 0 51 32% 19 30% 20 37% 9 39% 3 18%
1 81 52% 35 56% 26 48% 10 44% 10 59%
2 25 16% 9 14% 8 15% 4 17% 4 24%
Stage I 13 8% 4 6% 5 9% 2 9% 2 12%
II 16 10% 9 14% 2 4% 4 17% 1 6%
III 113 72% 45 71% 45 83% 10 43% 13 76%
Unknown 15 10% 5 8% 2 4% 7 30% 1 6%
Thoracic radiotherapy Once daily: 84 54% 29 46% 33 61% 14 61% 8 47%
Twice daily: 73 46% 34 54% 21 39% 9 39% 9 53%
Table 1 Baseline characteristics
Condition CCI-score n %
Chronic obstructive pulmonary disease 1 60 38%
Peptic ulcer disease 1 19 12%
Myocardial infarction (MI) 1 17 11%
Diabetes 1 17 11%
Peripheral vascular disease (PVD) 1 12 8%
Cerebrovascular disease (CVD) 1 12 8%
Connective tissue disease 1 8 5%
Congestive heart failure (CHF) 1 2 1%
Dementia 1 1 1%
Mild liver disease 1 1 1%
Tumour last 5 years 2 3 2%
Hemiplegia 2 - -
Moderate severe renal disease 2 - -
Diabetes with organ damage 2 - -
Lymphoma 2 - -
Leukaemia 2 - -
Moderate-severe liver disease 3 - -
Metastatic solid tumour 6 - -
AIDS 6 - -
Table 2 Comorbidity scores specified in the Charlson Comorbidity Index – and the 
frequency of each condition in our study population












Chemotherapy Completed all four courses 86% 94% 82% 83% 77% .09
No dose reduction 44% 52% 33% 57% 29% .07
Mean dose-intensity 92% 93% 91% 94% 89% .25
Received second-line chemotherapy 48% 57% 50% 44% 12% .010
Radiotherapy Thoracic radiotherapy completed as planned 97% 98% 94% 96% 100% .54
Received prophylactic cranial irradiation 83% 89% 76% 83% 82% .30










Any grade 3-5 haematological 89% 87% 88% 100% 82% .23
Anaemia 18% 19% 17% 22% 12% .86
Neutropenia 83% 87% 82% 91% 65% .13
Thrombocytopenia 41% 40% 44% 39% 35% .94
Any grade 3-5 non-haematological 69% 68% 69% 74% 69% .98
Neutropenic infections 41% 41% 39% 48% 35% .86
Radiation esophagitis 32% 38% 28% 35% 18% .36
Radiation pneumonitis 5% 5% 4% 9% 6% .76
Any grade 3-5 toxicity* 92% 89% 92% 100% 94% .49
Treatment related deaths CCI Co-existing conditions Age
Coronary heart disease 3
Myocardial infarction, congestive heart failure and 
chronic obstructive pulmonary disease (COPD)
62
Radiation pneumonitis 2 Cerebrovascular disease and COPD 75
Haemoptysis 1 COPD 69
Radiation pneumonitis 1 COPD 62
Respiratory failure 1 Peripheral vascular disease 76
Radiation pneumonitis 1 Peripheral vascular disease 73
Radiation pneumonitis 0 - 65
Table 4 Treatment toxicity and treatment-related deaths
* Grade 5 toxicity was observed in 4 patients with pneumonitis (CCI 0: n=1, CCI 1: n=2, CCI 2: n=1; p=.70)












n % n % n % n % n %
Complete response 35 22% 13 21% 9 17% 6 26% 7 41%
Partial response 106 68% 47 75% 38 70% 14 61% 7 42%
Stable disease 2 1% 1 2% 1 2% - - - -
Progressive disease 8 5% 2 3% 3 6% 3 13% - -
Not evaluable 6 4% - - 3 6% - - 3 18% .026
Overall response rate 141 90% 60 95% 47 87% 20 87% 10 77% .20
Table 6 Multivariate survival analysis
Variables* Hazard ratio 95% CI p
Age 1.01 0.99 1.04 .27
Gender Female 1
Male 0.96 0.65 1.41 .82
Thoracic radiotherapy OD 1
BID 1.16 0.79 1.71 .45
Stage I 1
II 0.48 0.19 1.22
III 1.10 0.58 2.09 .10
PS 0 1
1 1.09 0.71 1.66
2 1.39 0.79 2.45 .52
CCI 0 1
1 1.43 0.93 2.20
2 1.04 0.55 1.98
3-5 0.77 0.38 1.59 .23
*Age was entered as a continuous variable. Female sex, once daily radiotherapy, stage I, PS 0 and CCI 0 were reference 
categories for categorical variables. Overall p-value is presented for variables with more than two categories. 
